As of 2025-06-30, the EV/EBITDA ratio of C4 Therapeutics Inc (CCCC) is -0.42. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CCCC's latest enterprise value is 48.12 mil USD. CCCC's TTM EBITDA according to its financial statements is -114.73 mil USD. Dividing these 2 quantities gives us the above CCCC EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 11.5x - 13.3x | 12.7x |
| Forward P/E multiples | 17.9x - 27.3x | 22.4x |
| Fair Price | (28.13) - (20.77) | (27.67) |
| Upside | -2109.6% - -1583.3% | -2076.7% |
| Date | EV/EBITDA |
| 2025-06-27 | -0.42 |
| 2025-06-26 | -0.49 |
| 2025-06-25 | -0.51 |
| 2025-06-24 | -0.52 |
| 2025-06-23 | -0.46 |
| 2025-06-20 | -0.43 |
| 2025-06-18 | -0.44 |
| 2025-06-17 | -0.48 |
| 2025-06-16 | -0.56 |
| 2025-06-13 | -0.59 |
| 2025-06-12 | -0.56 |
| 2025-06-11 | -0.49 |
| 2025-06-10 | -0.52 |
| 2025-06-09 | -0.59 |
| 2025-06-06 | -0.62 |
| 2025-06-05 | -0.46 |
| 2025-06-04 | -0.51 |
| 2025-06-03 | -0.47 |
| 2025-06-02 | -0.38 |
| 2025-05-30 | -0.33 |
| 2025-05-29 | -0.37 |
| 2025-05-28 | -0.33 |
| 2025-05-27 | -0.36 |
| 2025-05-23 | -0.41 |
| 2025-05-22 | -0.40 |
| 2025-05-21 | -0.39 |
| 2025-05-20 | -0.47 |
| 2025-05-19 | -0.51 |
| 2025-05-16 | -0.41 |
| 2025-05-15 | -0.41 |
| 2025-05-14 | -0.40 |
| 2025-05-13 | -0.48 |
| 2025-05-12 | -0.53 |
| 2025-05-09 | -0.46 |
| 2025-05-08 | -0.51 |
| 2025-05-07 | -0.48 |
| 2025-05-06 | -0.43 |
| 2025-05-05 | -0.56 |
| 2025-05-02 | -0.63 |
| 2025-05-01 | -0.56 |
| 2025-04-30 | -0.57 |
| 2025-04-29 | -0.53 |
| 2025-04-28 | -0.56 |
| 2025-04-25 | -0.51 |
| 2025-04-24 | -0.55 |
| 2025-04-23 | -0.55 |
| 2025-04-22 | -0.52 |
| 2025-04-21 | -0.42 |
| 2025-04-17 | -0.33 |
| 2025-04-16 | -0.23 |